表紙
市場調査レポート

メディカルアフェアーズの評判 (EU5カ国) :炎症性疾患におけるバイオシミラーモノクロナール抗体 (バイオシミラー mAb)

Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders

発行 FirstWord 商品コード 326365
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
メディカルアフェアーズの評判 (EU5カ国) :炎症性疾患におけるバイオシミラーモノクロナール抗体 (バイオシミラー mAb) Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders
出版日: 2015年02月01日 ページ情報: 英文
概要

当レポートでは、英国、フランス、ドイツ、スペインおよびイタリアにおける150人のリウマチ専門医、皮膚科医、および胃腸科専門医を対象に実施した調査の結果に基づき、企業のメディカルアフェアーズチームによるバイオシミラー抗TNFモノクロナール抗体 (mAb) の開発とマーケティングを、様々なサポート役割において、いかに医師のニーズに適応させるかについて分析しており、抗TNF開発企業のメディカルアフェアーズチームの比較分析とともに、お届け致します。

主な調査内容

  • メディカルアフェアーズチームの良い点・悪い点を明らかにし、改善の主要ポイントを特定した、EU5カ国150人のリウマチ専門医、皮膚科医、および胃腸科専門医による詳細・タイムリーな分析
  • 現在の医師とメディカルアフェアーズチームの接点の調査
  • 医師が最も価値を置く・置かないメディカルアフェアーズチームの特性
  • EU5ヶ国それぞれの詳細データ分析
  • ニーズギャップ分析、FirstWordによる特性分析、現在のアンメットニーズの特定
目次
Product Code: 596200353

Based on survey results from 150 rheumatologists, dermatologists, and gastroenterologists in UK, France, Germany, Spain and Italy, ‘Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders’ offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal antibodies (mAbs) can best meet physician needs on various supporting roles. In addition, gain comparative insights on the Medical Affairs teams' roles from the originator anti-TNF companies.

Using Need-Gap analysis, a proprietary analytics tool to FirstWord, areas of unmet need are identified, which provide valuable guidance on opportunities for corporate and brand positioning and communication.

With the launch of biosimilar Remicade, and anti-TNF mAb, currently taking place across the major markets of Europe - France, Germany, Italy, Spain, the UK; EU5 - biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs' strategy for their products. Refining performance through smarter delivery, higher quality interaction, and effective communication with rheumatologists, dermatologists and gastroenterologists becomes vital for ensuring optimal performance levels of Medical Affairs teams.

Key Benefits

  • Review analysis of 150 EU5 rheumatologists/dermatologists/gastroenterologists' interactions with Medical Affairs teams highlighting good and bad performance, and identifying key areas for improvement
  • Gain detailed insights on how Medical Affairs teams from originator and biosimilar anti-TNF companies can improve physician satisfaction across a range of key performance attributes
  • Understand the key areas physicians prefer to interact with Medical Affairs Teams from the originator and biosimilar anti-TNF companies
  • Identify usage of 5 originator anti-TNFs, and which products are prescribed most
  • Learn what physicians believe are the most, and least, important attributes of Medical Affairs team engagement, and how these rate across originator and biosimilar anti-TNF companies
  • Gain insights on how Medical Affairs teams can provide better service to physicians

Report Features

Filled with charts and up-to-the-minute survey analysis, this report offers:

  • Precise and timely analysis of 150 EU5 rheumatologists/dermatologists/gastroenterologists' interactions with Medical Affairs teams highlighting good and bad performance and identifying key areas for improvement
  • Examination of physicians' current touch points with Medical Affairs teams
  • Key findings regarding the attributes of Medical Affairs teams physicians value most and least
  • Detailed data broken down by each EU5 country
  • Need-Gap analysis, a proprietary analytics tool to FirstWord, identifies current unmet needs

Top Takeaways

  • Insights on the current status of support and interactions with Medical Affairs teams from the originator anti-TNF companies and biosimilar anti-TNF companies
  • Expectations of support and interactions with Medical Affairs teams from biosimilar anti-TNF companies
  • Preferred contact frequency, form and other needs from the biosimilar anti-TNF companies
Back to Top